This is a preview of subscription content, log in via an institution to check access.
Reference
Alkhatib N, et al. Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs : 25 Jul 2020. Available from: URL: http://doi.org/10.1007/s40256-020-00425-x
Rights and permissions
About this article
Cite this article
Genetically targeted bucindolol in NYHA III/IV HF not cost effective. PharmacoEcon Outcomes News 859, 16 (2020). https://doi.org/10.1007/s40274-020-7025-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7025-9